About
Data Summary
Data Updates
RSV vaccination coverage estimates among adults 75 years and older and 50─74 years with high-risk conditions for RSV are based on self-reported data from CDC’s National Immunization Survey-Fall Respiratory Virus Module (FRVM). Data and charts are available.
As of December 13, 2025, among adults 75 years and older:
- An estimated 42.0% (95% Confidence Interval: 39.1%─44.9%) reported having ever received an RSV vaccine.
- An additional 5.5% (3.4%─7.5%) reported they definitely will get a vaccine.
- Vaccination coverage varied by disability status, health insurance status, poverty status, race and ethnicity, urbanicity, and presence of a chronic medical condition.
As of December 13, 2025, among adults 50─74 years with a high-risk condition for RSV:
- An estimated 31.1% (28.5%─33.7%) reported having ever received an RSV vaccine.
- An additional 13.5% (10.4%─16.5%) reported they definitely will get a vaccine.
- Vaccination coverage varied by age, health insurance status, poverty status, and race and ethnicity.
The summaries for the 2025─26 season will be populated as the data become available throughout the fall/Winter.
RSV vaccination coverage among Medicare fee-for-service beneficiaries 75 years and older and enrolled in a Part D plan is assessed using data files from the Medicare Fee-For-Service administrative claims data managed by the Centers for Medicare & Medicaid Services. Data and charts are available.
- As of September 27, 2025, an estimated 34.4% of Medicare fee-for-service beneficiaries 75 years and older enrolled in a Part D plan were vaccinated.
- Vaccination coverage was highest among White, non-Hispanic beneficiaries (35.3%) and lowest among Hispanic beneficiaries (13.1%).
IQVIA measures RSV vaccinations administered at retail pharmacies and American Medical Association (AMA) physicians’ medical offices for all adults 50 years and older (regardless of presence of high-risk conditions for RSV), based on healthcare claims data. Data and charts are available.
- During August 12, 2023, through November 29, 2025, in retail pharmacies and physicians' medical offices combined:
- An estimated ~237,875 doses of RSV vaccines were administered among all adults 50─59 years.
- An estimated ~9.21 million doses of RSV vaccines were administered among all adults 60─74 years.
- An estimated ~7.20 million doses of RSV vaccines were administered among all adults 75 years and older.
The summaries for the 2025─26 season will be populated as the data become available throughout the fall/Winter.
Monthly estimates of infant protection against RSV by maternal RSV vaccination or receipt of monoclonal antibody, as well as intent for monoclonal antibody receipt, reported by females 18─49 years with infants <8 months during the RSV season (born since April 1, 2025) are based on data from CDC’s National Immunization Survey-Fall Respiratory Virus Module (FRVM). Data and charts are available.
- As of November 2025, among females with an infant born since April 1, 43.2% of infants were reported to be protected against RSV through either maternal immunization only (3.6%) or receipt of monoclonal antibody (39.6%); an additional 18.3% reported that they would definitely get monoclonal antibody for their infants.
The summaries for the 2025─26 season will be populated as the data become available throughout the fall/Winter.
Data & Charts
Data & Charts
Archived Season Data & Charts
- Adults 60+ RSV Vaccination Coverage (NIS)
- Adults 75+ RSV Vaccine Administration and Coverage by Jurisdiction (IIS)
- Adults 75+ RSV Vaccination Coverage (CMS)
- Adults 60+ RSV Vaccines Administered (IQVIA)
- Pregnant Women RSV Vaccination Coverage (VSD)
- Nirsevimab Coverage (NIS)
- Nirsevimab Administration & Coverage by Jurisdiction (IIS)
Prevent RSV
Adults 50 years and older and pregnant women can protect themselves from RSV.
Learn more about RSV.